Product image of Kyntheum (Brodalumab) supplied by GNH India

Kyntheum

Active Ingredient:
Brodalumab
Origin:
EU

Kyntheum (Brodalumab)

Brodalumab, the active ingredient in Kyntheum, is a monoclonal antibody (IL‑17 receptor A antagonist) presented as a subcutaneous formulation for injection use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who require systemic therapy.

GNH India supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, cold‑chain logistics and regulatory compliance for biologic medicines. Our network facilitates reliable access to biologic therapies across diverse markets.

Manufacturer / TM Owner

Leo Pharma A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kyntheum is a biologic therapy that targets the IL‑17 pathway in inflammatory skin disease.

  • Plaque psoriasis: reduces erythema, scaling and plaque thickness, leading to improved skin appearance.
  • Moderate to severe disease: offers systemic control when topical therapies are insufficient.
  • Adult patients: provides an alternative for those who have not responded to other systemic agents.

How It Works

  • Brodalumab binds with high affinity to the interleukin‑17 receptor A (IL‑17RA) on the surface of keratinocytes and immune cells, blocking the downstream signaling of IL‑17A, IL‑17F and related cytokines. This inhibition dampens the inflammatory cascade that drives keratinocyte proliferation and plaque formation in psoriasis, resulting in clinical improvement of skin lesions.

Side Effects

Kyntheum may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

  • Injection site reactions: redness, swelling or pain at the injection site.
  • Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

  • Suicidal ideation or behavior: new or worsening thoughts of self‑harm.
  • Severe infections: including cellulitis, pneumonia or opportunistic infections.
  • Neutropenia: markedly reduced neutrophil counts increasing infection risk.
  • Allergic reactions: anaphylaxis or severe hypersensitivity.
  • Inflammatory bowel disease flare: new or worsening symptoms of Crohn's disease or ulcerative colitis.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient history and monitor for specific safety concerns.

  • Infection screening: evaluate for active or latent infections, especially tuberculosis.
  • Mental health assessment: monitor for depression, suicidal thoughts or behavior throughout treatment.
  • Immunization status: administer necessary vaccines before starting therapy; avoid live vaccines during treatment.
  • Laboratory monitoring: periodic complete blood count and liver function tests are recommended.
  • Pregnancy and lactation: limited data; weigh potential benefits against unknown risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Avoid Interactions

Brodalumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid)

  • Live vaccines: concurrent use can cause uncontrolled infection.
  • Systemic immunosuppressants (e.g., high‑dose corticosteroids): may markedly increase infection risk.

Moderate Interactions (Monitor Closely)

  • Other biologics targeting cytokines: overlapping immunomodulation may heighten adverse events.
  • Antifungal agents (e.g., azoles): may affect infection susceptibility.
  • Cytochrome P450 substrates: monitor for altered drug levels, although brodalumab itself is not a strong CYP modulator.

Frequently Asked Questions

Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who need systemic therapy. By targeting the IL‑17 pathway, it helps reduce skin redness, scaling and plaque thickness, improving overall skin appearance and quality of life.

Brodalumab is a monoclonal antibody that binds to interleukin‑17 receptor A (IL‑17RA). This blocks signaling from several IL‑17 cytokines, which are key drivers of inflammation in psoriasis. Inhibiting this pathway reduces keratinocyte activation and the formation of psoriatic plaques.

The dosing regimen for Kyntheum is determined by the prescribing clinician based on the patient’s clinical condition, weight and response to therapy. It is administered by subcutaneous injection according to the prescriber’s instructions and local regulatory guidelines.

Safety data for brodalumab during pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and the potential benefits must be weighed against possible risks. Clinicians should discuss the uncertainty with patients and consider alternative therapies when appropriate.

To request Kyntheum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Kyntheum (brodalumab) targets the IL‑17 receptor A, whereas agents such as secukinumab and ixekizumab bind directly to IL‑17A. This broader receptor blockade may offer efficacy in patients who have not responded to other IL‑17A‑specific antibodies, but safety profiles and dosing schedules differ, so individual patient factors guide selection.

Kyntheum must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If a dose is not used immediately, it may be kept at room temperature for a limited period as specified in the product labeling.

Kyntheum is given as a subcutaneous injection, typically in the thigh, abdomen or upper arm. Injection sites should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained patient following the prescriber’s instructions and aseptic technique.

Serious adverse events include suicidal ideation or behavior, severe infections (including opportunistic pathogens), neutropenia, and possible exacerbation of inflammatory bowel disease. Patients should be monitored closely for mood changes, signs of infection and abnormal blood counts throughout therapy.

Kyntheum is contraindicated in individuals with known hypersensitivity to brodalumab or any excipients. It should also be avoided in patients with active serious infections, uncontrolled tuberculosis, or those who are pregnant without a clear benefit‑risk assessment. Clinicians must evaluate each patient’s medical history before initiating treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Brodalumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT